Vanta Bioscience
25.64
0.00(0.00%)
Market Cap₹16.20 Cr
PE Ratio-
IndustryHealthcare
Company Performance:
1D0.00%
1M-10.26%
6M-18.60%
1Y-52.59%
5Y-84.48%
View Company Insightsright
Latest news about Vanta Bioscience
Vanta Bioscience Reports Significant Losses for FY2025 Amid Revenue Decline Aug 01, 2025
Vanta Bioscience Limited, a preclinical contract research organization, reported a substantial net loss for FY2025. Standalone net loss was Rs 265.95 lakh, compared to a profit of Rs 5.11 lakh in the previous year. Revenue from operations declined by 86.80% to Rs 112.74 lakh. Consolidated results showed a net loss of Rs 477.49 lakh, with revenue falling by 79.80% to Rs 196.36 lakh. The company faced operational challenges, including delays in consolidating financial results due to late receipt of accounts from an associate company. Despite financial difficulties, total assets increased by 2.52% to Rs 52.90 crore, while current liabilities rose by 39.22% to Rs 14.20 crore.